SMAGP Fusion Molecules Modulate Leukocyte Activity
Summary
USPTO published patent application US20260098070A1 disclosing fusion molecules comprising a SMAGP extracellular domain designed to modulate leukocyte activity. The application covers polynucleotides, vectors, and host cells encoding these molecules along with methods of making and using them. Inventors include Loise M. Francisco-Anderson, Sandeep Kumar, Sarah Elizabeth Carden, Christophe Quéva, and Nenad Grmusa, with filing date July 7, 2025.
What changed
USPTO published patent application US20260098070A1 disclosing SMAGP extracellular domain fusion molecules designed to modulate leukocyte activity, with potential therapeutic applications in cancer and inflammatory diseases. The application covers the molecules themselves, encoding polynucleotides, expression vectors, host cells, and methods of using the fusion molecules to influence immune cell function.
For biotechnology and pharmaceutical companies in the immunotherapy space, this publication establishes prior art as of the July 2025 filing date. R&D programs targeting leukocyte modulation pathways overlapping with SMAGP should conduct freedom-to-operate analyses. Licensees and investors in immune-oncology may find this IP relevant to competitive landscape assessments.
What to do next
- Monitor for USPTO examination updates and potential patent grant
- Review claims for freedom-to-operate considerations in leukocyte modulation space
- Assess licensing opportunities if working in immunotherapy or inflammatory disease
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SMAGP FUSION MOLECULES AND METHODS OF USE THEREOF
Application US20260098070A1 Kind: A1 Apr 09, 2026
Inventors
Loise M. Francisco-Anderson, Sandeep Kumar, Sarah Elizabeth Carden, Christophe Quéva, Nenad Grmusa
Abstract
Provided herein are fusion molecules comprising a SMAGP extracellular domain that can modulate leukocyte activity. Also provided are polynucleotides, vectors, and host cells encoding these fusion molecules, and methods of making and using these fusion molecules.
CPC Classifications
C07K 14/475 A61K 9/51 A61K 31/7088 A61K 35/76 A61K 38/00 A61K 51/00 A61P 35/00 C12N 15/62 C12N 15/63 G01N 33/68 C07K 2317/41 C07K 2317/53 C07K 2319/00 G01N 2333/70596 G01N 2500/02 G01N 2500/20
Filing Date
2025-07-07
Application No.
19260916
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.